Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

228
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
228
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation of serum galactomannan antigen with diagnosis and response to voriconazole in orbital/sino-orbital invasive aspergillosis.

International ophthalmology·2021
Same author

DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020
Same author

Cataract surgery in a case of Rosai-Dorfman disease with proptosis.

Journal of cataract and refractive surgery·2018
Same author

A study of changes in levator muscle in congenital ptosis.

International ophthalmology·2018
Same author

Ultrasound biomicroscopy image patterns in normal upper eyelid and congenital ptosis in the Indian population.

Indian journal of ophthalmology·2018
Same author

S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.

Journal of thrombosis and haemostasis : JTH·2016

Related Experiment Videos

Tissue factor pathway inhibitor: potential therapeutic applications

M S Bajaj1, S P Bajaj

  • 1Department of Internal Medicine, Saint Louis University School of Medicine, MO, USA. BajajMS@wpogate.slu.edu

Thrombosis and Haemostasis
|July 1, 1997
PubMed
Summary

Tissue factor pathway inhibitor (TFPI) is a key regulator of blood clotting. Animal studies show TFPI and anti-TF antibodies may treat diseases like sepsis and stroke.

Related Experiment Videos

Area of Science:

  • Coagulation cascade and hemostasis
  • Vascular biology and endothelial function
  • Thrombosis and its role in disease

Background:

  • The tissue factor (TF) pathway is central to normal hemostasis.
  • Tissue factor pathway inhibitor (TFPI) is the primary physiological inhibitor of TF-driven coagulation.
  • TF-initiated coagulation is implicated in numerous pathological conditions, including sepsis, stroke, and cancer.

Purpose of the Study:

  • To review animal studies investigating TF-induced coagulation inhibition.
  • To discuss the therapeutic potential of recombinant TFPI (rTFPI) in human diseases.

Main Methods:

  • Review of preclinical animal studies on TF pathway inhibition.
  • Analysis of clinical trial data for rTFPI in sepsis and microvascular surgery.

Main Results:

  • Animal studies demonstrate beneficial effects of anti-TF monoclonal antibodies and rTFPI in various disease models.
  • rTFPI is currently under investigation in human clinical trials for sepsis and post-microvascular surgery.

Conclusions:

  • Inhibition of the TF pathway shows therapeutic promise.
  • rTFPI represents a potential treatment strategy for TF-driven pathologies.